Innovative Medicines Initiative (IMI2) - UK

Grant programme focusing on improving health outcomes by speeding up the development of, and patient access to, innovative medicines.

Who it’s for

IMI calls for proposals are competitive and open to consortia which can be made up of members from:

  • healthcare research organisations, including universities
  • pharmaceutical and other industries
  • small and medium-sized enterprises (SMEs)
  • patient organisations
  • medicines regulators

The organisations can be based in England, Scotland, Wales or Northern Ireland.


IMI is a public-private partnership between the European Community, represented by the European Commission, and EFPIA.

Find out more on the IMI website
Published 31 October 2017